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The past decade has been a time of important change in pharmacogenomics. There is an
increasingly clear understanding of the relationship between genetic variation and drug
response, low-cost testing technologies are becoming available, and pharmacogenomics is
playing an increasing role in drug development. Key stakeholders in the U.S. healthcare
system are responding to these changes in various fashions. In this commentary, we provide
a brief overview of these developments.
Academic research
Academic researchers are pursuing innovative approaches to discover novel
pharmacogenomic variants, evaluating their potential clinical use, and addressing barriers to
implementation in medical practice. For example, researchers are conducting collaborative
genome-wide association studies (GWAS) to identify novel ‘druggable’ targets for further
development by the pharmaceutical industry, and evaluating the comparative effectiveness
of pharmacogenomic testing in multi-center randomized controlled trials (RCTs) for both
warfarin and clopidogrel therapy. The Pharmacogenomics Research Network (PGRN) is
facilitating the incorporation of pharmacogenomic information in the medical record,
working with underserved populations that have not traditionally participated ingenomics
research, and developing guidelines through its Clinical Pharmacogenetics Implementation
Consortium (CPIC) to assist clinicians in the use of test information.1, 2Complementing this
effort is the Electronic Medical Records and Genomics (eMERGE) network, an NIH-funded
consortium that seeks to integrate clinical data from electronic medical records with genetic
samples and eventually incorporate pharmacogenomic findings and genomic medicine into
clinical care.3
Pharmaceutical industry
The pharmaceutical industry is increasingly using pharmacogenomic strategies to identify
patient subgroups with improved benefit-risk profiles. For example, lumiracoxib is a
cyclooxygenase II inhibitor that initially received a non-approvable letter from the FDA due
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to hepatotoxicity.4 Novartis has discussed seeking approval for lumiracoxib in combination
with a genetic test to screen for major histocompatibility complex (MHC) variants
associated with liver injury. Similarly, a recent study by GlaxoSmithKline investigators has
identified MHC genetic variants associated with liver damage in response to lapatinib,
which is already FDA-approved for the treatment of breast cancer.4Pharmacogenomics of
acquired (i.e., tumor) genomic variation is playing an increasing role in the efficacy of
cancer drugs. The EGFR tyrosine kinase inhibitors erlotinib and gefitinib recently have been
shown to be more effective in patients with non-small cell lung cancer (NSCLC) who have
certain EGFRtumor mutations, and Pfizer is developing another drug for NSCLC, crizotinib,
which is projected to be indicated for 3–5% of patients with an EML4-ALK fusion gene
variation.5
Clinicians and patients
The perspectives of clinicians and patients regarding pharmacogenomics continue to evolve.
A recent study reported that patients wanted information about why a pharmacogenomic test
is needed and what the test results mean.6 Healthcare professionals, on the other hand,
appeared to focus on both the predictive accuracy and waiting time for a test result.6 Several
specialty professional organizations have released guidelines regarding pharmacogenomic
testing. For example, the American Society of Clinical Oncology (ASCO) recommends
KRAS mutation screening for patients with metastatic colorectal carcinoma who are
candidates for anti-EGFR antibody therapy. By contrast the American College of
Cardiology (ACC) Foundation/American Heart Association (AHA) recommends against
routine genetic testing prior to clopidogrel initiation, but suggests that such testing could be
considered in some high risk patients.7–8
Managed care organizations and benefits managers
Managed care organizations have approached reimbursement for pharmacogenomic testing
on a test-by-test basis. For cases in which a clear and compelling need exists, coverage and
reimbursement usually have been provided; for example for KRAS testing in colon cancer
and gene expression profiling in early stage breast cancer. In contrast, when the clinical
value has yet to be established, such as withCYP2D6 and CYP2C19 genotyping array,
reimbursement is not available. Several large pharmacy benefits managers have taken a
proactive role in providing pharmacogenomics services, and in establishing the systems and
evidence base to support their use. These approaches reflect the opportunity to deploy
pharmacogenomic information within existing pharmacy services infrastructures.
Federal government
The federal government plays a central role in the development, evaluation, and regulation
of pharmacogenomics. In addition to the PGRN and eMERGE research networks, recent
NIH funding requests have focused on the integration of whole exome sequencing
information into clinical practice and a National Center for Advancing Translational
Sciences (NCATS) has been proposed with the mandate most likely including development
of pharmacogenomics tools to help fill the drug development pipeline.9 Furthermore, major
efforts in comparative effectiveness research (CER) undertaken as part of recent healthcare
reform are directed toward translational research in cancer genomics.
Systematic evidence evaluation on pharmacogenomics has been supported by the federal
government through the Agency for Healthcare Research and Quality (AHRQ), the Center
for Medicare and Medicaid Services (CMS), and the CDC’s National Office of Public
Health Genomics, which established the genomics-focused group EGAPP.10 EGAPP has
made eight recommendations to date, including three on pharmacogenomic tests. CMS
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recently issued a national coverage decision for warfarin pharmacogenomic testing, stating
there is sufficient evidence to support “coverage with evidence development,” a
classification that pays for testing in an RCT setting.
The FDA has increased its efforts to review pharmacogenomics data submitted by drug
companies and has made several notable updates to drug labels (e.g. warfarin and
clopidogrel) to include pharmacogenomic information. However, the FDA does not require
pharmacogenomic testing for any specific drugs, with the exception of testing for specific
tumor mutations in cancer or viral genotypes. In addition, the FDA recently released a draft
guidance on the use of genomic data in early clinical trials that emphasizes the value of
collecting genetic samples from patients enrolled in studies, which may increase the use of
pharmacogenomics in drug development.
Implications for clinical practice
While use of genomics to guide treatment decisions is becoming more common in oncology,
relatively few tests are in use in other disease areas. Whole-exome assays likely will
introduce a new approach in genomics with the potential for extremely low cost tests on a
per genotype basis, and the possibility of obtaining genomic information before it is needed
clinically. A critical question facing clinicians will be the evidence thresholds for using such
information in practice. There are no uniform evidentiary standards for clinical
implementation, but frameworks have been created by groups such as EGAPP and
CPIC.2, 10Clinicians considering a pharmacogenomic test should consider several key
questions.(Table). Most importantly, clinicians should not be early adopters of a test until a
relationship has been established between the test result and drug response, and the findings
have been validated in rigorously conducted studies.
Ultimately clinicians and healthcare systems will have to decide which frameworks are best
suited for their needs. For example, will RCT-level data on safety and efficacy be required,
as for new drugs and biologics? Or will plausible benefit based on mechanisms and indirect
evidence be sufficient, as for drug-drug interactions? The answer will depend on the
specifics of the gene, drug, and disease, but novel decision-making frameworks would be
helpful in resolving conflicting stakeholder perspectives on this issue. In summary,
clinicians should expect a challenging yet exciting period over the next five years, with a
measured pace of introduction of new pharmacogenomic information and the beginning of a
transition to whole-exome sequencing.
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